International Registry for Mechanically Assisted Circulatory Support (IMACS)

 
IMACS logoRegistry data collection is currently paused as ISHLT works with registry partners in Europe, UK, and Japan on updating data privacy compliance and processes. Additional information will be available in late 2023.

The International Society for Heart and Lung Transplantation Registry for Mechanically Assisted Circulatory Support (IMACS) is an international registry intended to enroll and follow patients who receive durable mechanically assisted circulatory support devices (MCSD) in all countries and hospitals that wish to participate. Durable devices are defined as those devices that are capable of allowing patient discharge with the device in place. Devices are defined on a country by country basis. The registry will record pre-implant patient information, device information and will track the major post implant clinical events.
 
The specific mission of IMACS is the promotion of scientific investigations and publications based on analyses of this multinational database, providing the opportunity for an international array of authors to collaborate in Registry investigations, presentations, and publications.
 
Goals
The primary goal of the IMACS Registry is to create, implement and analyze a registry that contains high standards for complete enrollment of patients and complete and accurate submission of MCSD data that allows participating centers to engage in important outcomes research about mechanical support devices.

Purpose
  • To capture worldwide data relating to the implantation and outcome of patients receiving cardiac assist devices designed for and capable of use for 30 or more days
  • To identify risk factors for complications
  • To improve patient selection and management before and after device implantation
  • To generate predictive models of outcome for given patient profiles
  • To generate statistical analyses of the data that can be used as the underlying evidence/ justification for government agency funded studies and clinical trials
  • To identify overall and best practices with the aim of improving current practices
 
Benefits to Centers
  • Statistical summaries of hospital experience
  • Benchmarks for comparison against the international experience
  • Description of performance standards for units and practitioners
  • Determine resources (personnel, skills, training) needed to meet performance standards
  • Participate in device research
  • Generate volume and trend data to facilitate short and long term financial planning
     
Benefits to ISHLT
  • Own and direct an international high quality MCSD registry
  • Complement the ISHLT transplant registry as ISHLT emphasizes its role in MCSD research
  • Provides Statistical Reports and Research Analyses to ISHLT Researchers
     
Benefits to MCS Community
  • Improved outcomes from new techniques and devices
  • Facilitate accelerated evaluation of new devices
  • Development of international standards for MCS therapy

See Also: Research Oversight Committee
 

Below are the Steering Committee Members who manage the IMACS Registry

Click on any card below to enlarge for more information. Only ISHLT Members who are logged in can view contact information on the enlarged card.
 
IMACS Registry Data Studies IMACS Registry Publications and Presentations True

Related Items

Daniel Goldstein MD

Chair

Montefiore Med Ctr
Bronx, New York, United States
Ryan Cantor MD

Biostatistician

Kirklin Solutions
AL, USA